Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30514816 | 1.00 | DRD2 (0.47) | DRD2LRRK2ACHEHTR4ALDH1A1 | |
| SCHEMBL30514833 | 1.00 | DRD2 (0.47) | DRD2LRRK2ACHEHTR4ALDH1A1 | |
| SCHEMBL10711348 | 0.83 | HTT (0.56) | ALDH1A1LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL21177577 | 0.83 | RAB9A (0.43) | ALDH1A1 | |
| SCHEMBL21177607 | 0.83 | RAB9A (0.43) | ALDH1A1 | |
| SCHEMBL21813217 | 0.81 | L3MBTL3 (0.52) | DRD2LRRK2ACHEHTR4ALDH1A1 | |
| SCHEMBL17502635 | 0.81 | KMT2A (0.65) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL30514818 | 0.80 | SMN1; SMN2 (0.54) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL21179375 | 0.80 | SMN1; SMN2 (0.54) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL21179377 | 0.80 | SMN1; SMN2 (0.54) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| WO-2019141694-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | PI4KB, PI4K2B, PI4K2A | DRD2 4832/4885LRRK2 795/4885ACHE 4270/4885 |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | PI4K2A, PI4K2B, PI4KA | DRD2 4490/4885LRRK2 1477/4885ACHE 3688/4885 |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | PI4KB, PI4K2B, PI4K2A | DRD2 4827/4885LRRK2 861/4885ACHE 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.